Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services – QNT Press Release


SUZHOU, China, Aug. 29, 2022 /PRNewswire/ — On August 20, 2022Porton Advanced Solutions (hereinafter referred to as “Porton Advanced”) and Kun Tuo Medical Research and Development (Beijing) Co., Ltd. (hereinafter referred to as “Kun Tuo“) established a strategic partnership in gene and cell therapy R&D, manufacturing and clinical services to accelerate the development and industrialization of innovative drugs.

Through this strategic cooperation, Porton Advanced and Kun Tuo will fully leverage their strengths, client resources and professional team capabilities to deepen cooperation in gene and cell therapy R&D, manufacturing and clinical research, providing one-stop CDMO and clinical research services for innovative drug companies and cooperating to establish a high-quality gene and cell therapy industry ecosystem.

Focusing on gene and cell therapy, Porton Advanced has built CDMO platforms for plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vector based gene therapy. In the process of gene and cell therapy drug development, Porton Advanced can provide CDMO services such as IND-CMC pharmacological research and clinical sample GMP production. Up to now,…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center